CTLA4 and neoplasm: Similarly to the CTLA-4/CD28 dynamic, TIGIT outcompete DNAM-1 (CD226) and CD96 for the binding of CD155, impeding DNAM-1 positive co-stimulation and delivering a direct inhibitory signal [103,104,106] as shown in TIGIT-deficient mice with delayed tumor growth [107].